NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









HepaTx Corporation

HepaTx Corporation

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://hepatx.com/

Last Round

Grant

May 20, 2025

Est. Valuation

$2.14M

Total Funding Raised

$475,032

Company Overview

HepaTx Corporation is a biotechnology company that specializes in regenerative medicine and the development of stem cell-based therapies for patients with late-stage liver disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicinecell therapyliver diseaseoff-the-shelf cell therapystem cell therapyallogeneic cell therapyorgan transplant alternativeend-stage liver diseaseliver cell therapyhepatocyte-like cellsadipose-derived stem cellsliver regenerationpre-clinical biotechNASHproteomic assayA1ATDPKUSBIRSmall Business Innovation Research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HepaTx Corporation Comparables

Compare HepaTx Corporation with similar companies based on industry and business-model similarity.

HepaTx Corporation comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

HepaTx Corporation Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 20, 2025
SeedMay 1, 2021
GrantSep 1, 2019
AcceleratorAug 21, 2018

HepaTx Corporation Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2025

    $176K grant from National Institute of Diabetes and Digestive and Kidney Diseases.

HepaTx Corporation Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HepaTx Corporation Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HepaTx Corporation's valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range3
Year Founded2015
Last FundingMay 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.